The Global High Potency API CDMOs Market is expected to witness a high and a single-digit growth by 2027. The principal factors fueling the market’s growth are growing demand for oncology medications, ...

AbbVie is investing $195 million in a new API facility in North Chicago, operational by 2027, to enhance US chemical synthesis capabilities. The investment is part of a $10 billion commitment to boost ...

Continuous manufacturing offers advantages in both biotherapeutic and API manufacturing but still poses challenges. The forward movement of the bio/pharmaceutical industry is driven by fast-paced ...

(MENAFN- IMARC Group) An API (Active Pharmaceutical Ingredient) is the biologically active component of a drug that produces the intended therapeutic effect. It is the essential substance in medicines ...

(MENAFN- IMARC Group) Setting up an API Manufacturing facility necessitates a detailed market analysis alongside granular insights into various operational aspects, including unit processes, raw ...

When the campus is complete, it will produce several of Lilly’s APIs and genetic medicines to serve US patients.